Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Career
    • Practice Management
      • Reimbursement & Coding
      • Legal
      • Operations
    • Awards
    • Certification
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Compensation Reports
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • By the Numbers
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • mTBI Resource Center
    • ACEP.org
    • ACEP Knowledge Quiz
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • Issue Archives
  • Archives
    • Brief19
    • Coding Wizard
    • Images in EM
    • Care Team
    • Quality & Safety
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Blood-Thinner Reversal Agent Works in 82% of Serious Bleeding Cases

By Reuters Staff | on March 8, 2019 | 1 Comment
Uncategorized
Share:  Print-Friendly Version

Portola financed, designed, and supervised the study, conducted at 63 centers in North America and Europe. The test is being extended to enroll additional patients in Germany and Japan.

You Might Also Like
  • Factor Xa Inhibitor Reversal Agent Is Not Ready for Prime Time
  • FDA Approves Praxbind as Reversal Agent for Pradaxa
  • NOAC Bleeding No More Dangerous than Warfarin Bleeding

Pages: 1 2 | Single Page

Topics: AndexxaAnticoagulantBleedingCoagulationfactor Xa inhibitorsStroke

Related

  • Case Report: A Pediatric Amputated Juvenile Polyp

    January 6, 2026 - 0 Comment
  • PCC versus Andexanet Alfa for Factor Xa Reversal

    October 9, 2025 - 0 Comment
  • Case Report: Rare Pulmonary Embolism After Routine PIVC Insertion

    September 22, 2025 - 1 Comment

Current Issue

ACEP Now: February 2026 (Digital)

Read More

One Response to “Blood-Thinner Reversal Agent Works in 82% of Serious Bleeding Cases”

  1. March 11, 2019

    jw Reply

    1) anticoagulant reversal agents do not stop bleeding, they mitigate effect of anticoagulant
    2) “blood thinners” do not “remove blood clots”, they alter the physiology of coagulation cascade

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*



Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603